Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cancer Pain 1

Interventions

Oxycodone 2resiniferatoxin 1Spinal Cord Stimulation 1Radiosurgery 1Radiofrequency Ablation 1Propofol 1Midazolam 1Lidocaine 1Ethanol 1Electroencephalography 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Cancer Pain × resiniferatoxin × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡